The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)
Key facts
- Who runs it
- Istituto Clinico Humanitas
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 19 Mar 2026
- Expected to end
- 19 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Diagnostic Test: Rapid Antimicrobial Susceptibility Testing (R-AST) guided Stewardship
- Standard of Care (SOC)
- Record updated
- 24 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients admitted to emergency department or hospitalized for any cause in participating hospitals with clinically suspected BSI and positive blood culture
- At least 18 years of age
Who cannot take part
- Have previously taken part in this trial
- Patient with severe or terminal disease with life expectancy shorter than 48 h
- Concurrently participating in the active phase of a study considered incompatible
- Have an existing directive to withhold life-sustaining treatment, in relation to antibiotic use
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The ACT-FAST study aims to compare commercially available Rapid Antimicrobial Susceptibility Testing (R-AST) tools with the current standard of care for patients with Bloodstream Infections (BSI). The primary objective is to evaluate whether "early targeted" antibiotic prescriptions, guided by these rapid tests, can improve antimicrobial stewardship and patient clinical outcomes.
Read full original descriptionShow less
To facilitate the evaluation of various diagnostic tools-including those currently on the market and those emerging in the near future-this study utilizes an adaptive clinical trial platform. This flexible design allows for the continuous assessment of different R-AST technologies within a single master protocol, ensuring that the most effective diagnostic strategies are identified efficiently.
The 2 groups in the trial
- Experimental armTreatment being tested
Diagnostic approach to blood cultures using rapid microbiological diagnosis testing (R-AST)
Treatment: Diagnostic Test: Rapid Antimicrobial Susceptibility Testing (R-AST) guided Stewardship
- Standard of careExisting treatment, for comparison
Diagnostic approach to blood cultures using the standard method
Treatment: Standard of Care (SOC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome: a Randomized Clinical Trial Within an Adaptive Platform Trial for Patients With Bloodstream Infections
- Record updated
- 24 June 2026